Home / Knowledge hub /
Navigating the transition to next-generation propellants for pMDIs | On-demand webinar
December 10, 2025
Regulators, health systems and patients expect meaningful progress on sustainability. For pressurized metered dose inhalers (pMDIs), this means planning the transition to low global warming potential (low-GWP) next-generation propellants (NGPs) now, not at the end of the decade.
In this webinar with Pharmaceutical Technology, Craig Somerville, Senior Vice President of Kindeva’s pMDI business unit, shares a practical view of what it takes to move existing products to NGPs while maintaining performance, supply continuity and patient need for MDIs.
Drawing on Kindeva’s pMDI pedigree built on inventing and industrializing the MDI, and its current investments in commercial-scale NGP capability, Craig outlines how a strategic drug delivery CDMO partner can help you move from feasibility to full-scale commercial supply with confidence.
Highlights include:
- The drivers accelerating the shift to NGPs
- What NGP-ready manufacturing and reformulation require
- Key considerations for HFA-152a and maintaining equivalent MDI performance
- How regulators are approaching the transition
- Where Kindeva adds value from feasibility through to commercial supply
Watch the webinar →
Access this content
Fields marked with a * are required.
Related resources
Explore our other resources to discover valuable insights on the latest trends in drug delivery.
Parenteral precision: Upstream formulation handling before sterile fill finish
Parenteral precision is a blog series exploring the controls, technologies and design decisions that shape modern parenteral manufacturing. Each article looks at one capability through a practical lens: what it is, how it works, who it supports and why it matters. In our first blog, we explored how sterile fill finish operations are designed around […]
Learn More
Delivering tomorrow’s injectables, today
Injectable therapies are entering a new phase of complexity. Biologics, personalized medicines and combination products are increasing demand for delivery systems that must adapt to more diverse formats and patient needs. Expectations around speed and compliance also continue to rise across the development lifecycle, placing greater pressure on how these systems are designed and scaled. […]
Learn More
Green propellants and the future of metered dose inhalers
The transition to next-generation propellants (NGPs) with low global warming potential (GWP) is redefining what success looks like for pressurized metered dose inhalers (MDIs). As sustainability targets tighten, developers must rethink how inhaled therapies are formulated, tested and manufactured without compromising performance. Reformulating with NGPs affects not only the drug product but also its interaction […]
Learn More
Q&A: Navigating tech transfer and production pitfalls
Successful tech transfer alignment requires robust risk management and precise operational planning. When communication gaps or unforeseen supply chain hurdles emerge, project timelines and product quality are often the first to be affected. In this Q&A, we explore the common pitfalls of pharmaceutical tech transfers, including how to protect critical milestones without compromising safety and […]
Learn More
Webinar | Beyond the filling suite: How modular facility design supports sterile manufacturing success
Sterile manufacturing requirements are fast evolving, which means that many organizations are reassessing whether their legacy facilities can support future operational and regulatory demands. In this webinar, John Wichelt, Vice President and General Manager at Kindeva’s Bridgeton site, explores what a modern sterile fill finish facility needs to look like in this new era. Drawing […]
Learn More
What does Annex 1 mean for sterile drug product manufacturing?
Annex 1 compliance remains a key priority for companies working in sterile drug product manufacturing. But recognizing how fundamentally expectations around sterility assurance have changed may be the most significant challenge companies face. Revisions to the EU GMP Annex 1 requirements now move beyond individual compliance activities and place greater emphasis on how contamination risks […]
Learn More
Delivering value beyond manufacturing in nasal drug delivery
Nasal drug delivery has moved far beyond familiar allergy sprays, now supporting life-saving rescue therapies, complex systemic treatments and investigational nose-to-brain approaches. As this evolution and shift toward wider, more complex applications continue, so too will expectations for product quality and reliability. Behind every successful nasal product sits a delicate balance of interdependent elements. Formulation, […]
Learn More
Video tour | Explore Kindeva’s US manufacturing network
As a purpose-fueled, people-centric drug delivery CDMO, we are dedicated to advancing programs that help fast-track healthier tomorrows. Our US facilities play a vital role in delivering this commitment, providing specialized environments, technical depth and operational excellence that extend beyond manufacturing. Our US sites are strategically located and designed to support complex drug delivery programs […]
Learn More
Explore our world-class sterile injectable facility in Bridgeton, Missouri | Video tour
Spanning over 155,000 sq. ft. of dedicated aseptic operations space, our Bridgeton, MO facility brings together leading expertise, advanced automation and Annex 1-compliant isolator technology to help support growing global demand for sterile injectables. Designed to deliver excellence from floor to ceiling, Bridgeton seamlessly connects development and delivery through flexible fill finish infrastructure that helps […]
Learn MoreLet’s transform tomorrow together
Every patient deserves a brighter tomorrow. As your strategic partner, we are dedicated to building your lasting legacy and helping you fast-track healthier tomorrows. You dream it, we deliver it.